Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562715 | 0.90 | ITGB1 (0.77) | ITGA4ITGB1 | |
| SCHEMBL7246708 | 0.88 | ITGA4 (0.77) | ITGA4ITGB1 | |
| SCHEMBL6509932 | 0.87 | ITGB1 (0.68) | ITGA4ITGB1 | |
| SCHEMBL6510378 | 0.86 | ITGA4 (0.71) | ITGA4ITGB1 | |
| SCHEMBL6530110 | 0.85 | ITGB1 (0.83) | ITGA4ITGB1 | |
| SCHEMBL7260512 | 0.84 | ITGB1 (0.77) | ITGA4ITGB1 | |
| SCHEMBL6509079 | 0.84 | ITGB1 (0.84) | ITGA4ITGB1 | |
| SCHEMBL7610444 | 0.82 | ITGA4 (0.74) | ITGA4ITGB1 | |
| SCHEMBL4736989 | 0.82 | ITGA4 (0.77) | ITGA4ITGB1 | |
| SCHEMBL29646297 | 0.82 | ITGB1 (0.88) | ITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056714-B1 | PHENYLALANINE DERIVATIVES AS INHIBITORS OF ALPHA4 INTEGRINS | CELLTECH THERAPEUTICS LTD (GB) | 2004-08-11 | — | — | EP | claimed |
| US-6555562-B1 | 2-Carboxybenzoyl-(N'-3,5-dichloroisonicotinoyl)-L-4aminophenyl alanine, for example; inhibit the binding of alpha-4 integrins to their ligands, use to treat immune or inflammatory disorders | CELLTECH R&D LIMITED (GB) | 2003-04-29 | — | — | US | claimed |
| US-20050215598-A1 | Phenylalanine derivatives | CELLTECH R&D LTD. (GB) | 2005-09-29 | — | — | US | disclosed |
| EP-1056714-B1 | PHENYLALANINE DERIVATIVES AS INHIBITORS OF ALPHA4 INTEGRINS | CELLTECH THERAPEUTICS LTD (GB) | 2004-08-11 | — | — | EP | disclosed |
| US-20030166691-A1 | Phenylalanine derivatives | ARCHIBALD SARAH CATHERINE (GB) | 2003-09-04 | — | — | US | disclosed |
| US-6555562-B1 | 2-Carboxybenzoyl-(N'-3,5-dichloroisonicotinoyl)-L-4aminophenyl alanine, for example; inhibit the binding of alpha-4 integrins to their ligands, use to treat immune or inflammatory disorders | CELLTECH R&D LIMITED (GB) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166691-A1 | Phenylalanine derivatives | VCAM1, PAH, ITGB4 | ITGA4 4/4885ITGB1 6/4885 |
| US-20050215598-A1 | Phenylalanine derivatives | PAH, ITGB4, VCAM1 | ITGA4 4/4885ITGB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.